Abstract
Based on the promising results of preclinical studies, the synergistic activity between cytokines and chemotherapeutic agents has been investigated in clinical trials. Anti-tumor activity and alterations in the spectrum of toxicity of the single modalities have been reported. However, definitive evidence for clinically relevant synergy remains unproven. In addition, optimal doses and schedules of these combinations have not yet been determined. Uncovering the mechanism of action for a specific combination may allow future studies to exploit this preclinical synergy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 224-232 |
| Number of pages | 9 |
| Journal | Cancer Bulletin |
| Volume | 43 |
| Issue number | 3 |
| State | Published - 1991 |
ASJC Scopus subject areas
- Cancer Research